GIM
XBI icon

Glenmede Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Glenmede Investment Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$451K Hold
4,500
– – ﹤0.01% 968
2025
Q2 		$373K Buy
+4,500
New +$359K ﹤0.01% 1028

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Glenmede Investment Management's XBI Position: Q3 2025 in Review

Glenmede Investment Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2025 at 4,500 shares worth $451K. The position accounts for ﹤0.01% of the portfolio, ranked #968.

Glenmede Investment Management first reported a position in XBI in Q2 2025 and has held it in 2 quarters since. 656 funds tracked by Wall St. Rank hold XBI as of Q3 2025.

  • Glenmede Investment Management held 4,500 shares of State Street SPDR S&P Biotech ETF worth $451K as of Q3 2025.
  • Glenmede Investment Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2025.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #968 holding.
  • Glenmede Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2025 and has held it in 2 quarters since.
  • 656 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.